BeStock  
Stocks › Biotechnology › NVCT

Nuvectis Pharma NVCT

US equityMarket cap rank #3552Biotechnology
$20.29 +$0.26 (+1.30%)
Market closed · Oct 8, 5:40 am ET · Last extended-hours $20.29 0.00%
Open$19.67
Prev close$20.03
Day range$19.67 – $20.72
Volume121.1K
Market cap$662.35M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$7.20M-9.1% YoY
Net profit-$7.02M-10.8% YoY
Diluted EPS-$0.30+0.0% YoY
Free cash flow-$4.53M-34.6% YoY
Operating cash flow-$4.53M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-4.2MSep '24$-6.2MDec '24$-5.3MMar '25$-6.3MJun '25$-7.5MSep '25$-7.3MDec '25$-6.1MMar '26$-7.0MJun '26

Diluted EPS by quarter

-0.24Sep '24-0.36Dec '24-0.27Mar '25-0.30Jun '25-0.44Sep '25-0.31Dec '25-0.26Mar '26-0.30Jun '26

Free cash flow by quarter

$-2.4MSep '24$-2.5MDec '24$-4.2MMar '25$-3.4MJun '25$-4.5MSep '25$-4.0MDec '25$-6.5MMar '26$-4.5MJun '26

Annual revenue

$0.0FY21$0.0FY22$0.0FY23$0.0FY24$0.0FY25

Profitability & balance sheet

Return on equity-233.3%
Return on assets-122.6%
Return on invested capital-241.2%
Current ratio1.68
Liabilities / assets59.4%
Cash & investments$22.16M
Net cash (debt)$22.16M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Operating Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Operating Expense $7.20M $6.26M $27.57M $7.62M $7.79M
Selling and Admin Expenses $2.51M $2.15M $9.42M $2.53M $2.02M
-General & Admin Expense $2.51M $2.15M $9.42M $2.53M $2.02M
Research & Development $4.68M $4.11M $18.15M $5.09M $5.77M
Operating Profit -$7.20M -$6.26M -$27.57M -$7.62M -$7.79M
Net Non-Operating Interest Income (Expense) $177,000.00 $210,000.00 $1.13M $303,000.00 $332,000.00
Non-Operating Interest Income $177,000.00 $210,000.00 $1.13M $303,000.00 $332,000.00
Pretax Profit -$7.02M -$6.05M -$26.44M -$7.31M -$7.46M
Net Profit -$7.02M -$6.05M -$26.44M -$7.31M -$7.46M
Profit from Continuing Operations -$7.02M -$6.05M -$26.44M -$7.31M -$7.46M
Net Income to Parent Company -$7.02M -$6.05M -$26.44M -$7.31M -$7.46M
Net Income to Common Stockholders -$7.02M -$6.05M -$28.87M -$7.31M -$9.89M
Basic EPS -$0.30 -$0.26 -$1.32 -$0.31 -$0.44
Diluted EPS -$0.30 -$0.26 -$1.32 -$0.31 -$0.44
Other Preferred Stock Dividends – – $2.43M $0.00 $2.43M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $22.38M $25.40M $31.71M $31.71M $35.59M
Total Current Assets $22.38M $25.40M $31.71M $31.71M $35.59M
Cash and Cash Equivalents & Short-Term Investments $22.16M $25.13M $31.63M $31.63M $35.44M
-Cash and Cash Equivalents $22.16M $25.13M $31.63M $31.63M $35.44M
Other Current Assets $216,000.00 $268,000.00 $75,000.00 $75,000.00 $145,000.00
Total Non-Current Assets $0.00 $0.00 $0.00 $0.00 $0.00
Total Liabilities $13.29M $11.18M $13.30M $13.30M $11.58M
Total Current Liabilities $13.29M $11.18M $13.30M $13.30M $11.58M
Payables $5.18M $4.70M $6.27M $6.27M $6.51M
-Accounts Payable $5.18M $4.70M $6.27M $6.27M $6.44M
Current Accrued Expenses $92,000.00 $36,000.00 $115,000.00 $115,000.00 $65,000.00
Current Deferred Liabilities $1.39M – – – –
Total Non-Current Liabilities $0.00 $0.00 $0.00 $0.00 $0.00
Total Equity $9.08M $14.22M $18.41M $18.41M $24.01M
Stockholders' Equity $9.08M $14.22M $18.41M $18.41M $24.01M
Capital Stock $0.00 $0.00 $0.00 $0.00 $0.00
-Common Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $121.84M $119.96M $118.10M $118.10M $116.38M
Retained Earnings -$112.76M -$105.74M -$99.69M -$99.69M -$92.37M
-Other Payable – – – – $75,000.00

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$4.53M -$6.51M -$16.01M -$3.97M -$4.49M
Net cash flow from continuing operations -$4.53M -$6.51M -$16.01M -$3.97M -$4.49M
Net Income from Continuing Operations -$7.02M -$6.05M -$26.44M -$7.31M -$7.46M
Change in Working Capital $780,000.00 -$2.31M $4.40M $1.86M $1.51M
-Change in Payables and Accrued Expense $1.01M -$2.12M $3.05M -$115,000.00 $1.53M
-Change in Other Current Assets $52,000.00 -$193,000.00 -$1,000.00 $70,000.00 $69,000.00
Net cash flow from investing $0.00 $0.00 $0.00 $0.00 $0.00
Financing Cash Flow $1.56M $7,000.00 $29.11M $166,000.00 $13.14M
Net Cash Flow from Continuing Financing Activities $1.56M $7,000.00 $29.11M $166,000.00 $13.14M
Net Common Stock Issuance $1.57M $7,000.00 $31.21M $248,000.00 $13.55M
Ending Cash Balance $22.16M $25.13M $31.63M $31.63M $35.44M
Net Change in Cash -$2.97M -$6.50M $13.10M -$3.81M $8.65M
Beginning Cash Balance $25.13M $31.63M $18.53M $35.44M $26.79M
Free Cash Flow -$4.53M -$6.51M -$16.01M -$3.97M -$4.49M
-Change In Other Working Capital – – $1.35M $1.91M -$83,000.00
Net Other Financing Charges – – -$2.10M -$82,000.00 -$407,000.00

Discussion

No comments yet — be the first to weigh in on NVCT.

Leave a comment

Scroll to Top